answer
"If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is chronic, accelerated, or blast phase, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for adult patients with chronic, accelerated, or blast phase Philidelphia chromosome-positive (Ph+) CML with resistance or intolernace to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.)."
"If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is chronic phase, one recommended treatment would be Dasatinib. The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for newly diagnosed patients with Philidelphia chromosome-positive (Ph+) CML in chronic phase. It is also approved for adults with chronic, accelerated, myeloid, or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib. (Citation: Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf. Revised December 2018. Accessed November 12, 2020.)."
"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Dasatinib. The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for adults with Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (Citation: Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf. Revised December 2018. Accessed November 12, 2020.)."
"If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is chronic phase, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for newly diagnosed adult and pediatric patients with Philidelphia chromosome-positive (Ph+) CML in chronic phase. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.)."
"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.)."
"If a chronic myeloid leukemia patient has a rearrangement in gene BCR and ABL1, and is chronic phase, one recommended treatment would be Asciminib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval based on major molecular resposne to Scemblix (asciminib) for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). (Citation: Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf. Revised October 2021. Accessed November 3, 2021.)."
"If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.)."
"If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.)."
"If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.)."
"If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.)."
"If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.)."
"If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.)."
"If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is adults with previously treated, unresectable locally advanced or metastatic disease, one recommended treatment would be Infigratinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Citation: QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.)."
"If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.)."
"If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.)."
"If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.)."
"If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.)."
"If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.)."
"If a chronic eosinophilic leukemia patient has a rearrangement in gene FIP1L1 and PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with chronic eosinophilic leukemia (CEL) who have FIP1L1-PDGFRA fusions. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.)."
"If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.)."
"If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.)."
"If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.)."
"If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.)."
"If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.)."
"If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.)."
"If a prostate cancer patient has a somatic variant in gene ATM, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.)."
"If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.)."
"If a melanoma patient has a somatic variant in gene BRAF (c.1798_1799GT>AA or p.V600K), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.)."
"If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.)."
"If a melanoma patient has a somatic variant in gene BRAF (c.1798_1799GT>AA or p.V600K), one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.)."
"If a non-small cell lung cancer patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E, as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.)."
"If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf. Revised June 2020. Accessed November 12, 2020.)."
"If a melanoma patient has a somatic variant in gene BRAF (c.1798_1799GT>AA or p.V600K), and is unresectable or metastatic, one recommended treatment would be Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf. Revised June 2020. Accessed November 12, 2020.)."
"If a melanoma patient has a somatic variant in gene BRAF (c.1798_1799GT>AA or p.V600K), and is unresectable or metastatic, one recommended treatment would be Encorafenib. The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600K mutation, as detected by an FDA-approved test. (Citation: Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Encorafenib. The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test. (Citation: Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a colorectal cancer patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is metastatic, after prior therapy, one recommended treatment would be Cetuximab + Encorafenib. The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. (Citation: Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Vemurafenib. The U.S. Food and Drug Administration (FDA) granted regular approval to vemurafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test. (Citation: Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed November 12, 2020.)."
"If a epithelial ovarian cancer patient has a somatic variant in gene BRCA1, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a fallopian tube cancer patient has a somatic variant in gene BRCA1, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a ovarian cancer patient has a somatic variant in gene BRCA1, and is previously treated with 2 or more chemotherapies, one recommended treatment would be Rucaparib. Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies (Citation: Clovis Oncology, Inc. Rucaparib (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf. Revised October 2020. Accessed November 12, 2020.)."
"If a fallopian tube patient has a somatic variant in gene BRCA1, one recommended treatment would be Rucaparib. Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies (Citation: Clovis Oncology, Inc. Rucaparib (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf. Revised October 2020. Accessed November 12, 2020.)."
"If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is previously treated with 2 or more chemotherapies, one recommended treatment would be Rucaparib. Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies (Citation: Clovis Oncology, Inc. Rucaparib (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf. Revised October 2020. Accessed November 12, 2020.)."
"If a ovarian cancer patient has a somatic variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a fallopian tube cancer patient has a somatic variant in gene BRCA1, and is treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a epithelial ovarian cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a fallopian tube cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a fallopian tube cancer patient has a somatic variant in gene BRCA2, and is treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a fallopian tube cancer patient has a somatic variant in gene BRCA2, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a ovarian cancer patient has a somatic variant in gene BRCA2, and is previously treated with 2 or more chemotherapies, one recommended treatment would be Rucaparib. Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies (Citation: Clovis Oncology, Inc. Rucaparib (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf. Revised October 2020. Accessed November 12, 2020.)."
"If a fallopian tube patient has a somatic variant in gene BRCA2, and is previously treated with 2 or more chemotherapies, one recommended treatment would be Rucaparib. Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies (Citation: Clovis Oncology, Inc. Rucaparib (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf. Revised October 2020. Accessed November 12, 2020.)."
"If a ovarian cancer patient has a somatic variant in gene BRCA2, and is previously treated with 2 or more chemotherapies, one recommended treatment would be Rucaparib. Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies (Citation: Clovis Oncology, Inc. Rucaparib (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf. Revised October 2020. Accessed November 12, 2020.)."
"If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a fallopian tube cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a prostate cancer patient has a somatic variant in gene CHEK1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a prostate cancer patient has a somatic variant in gene CHEK2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2369C>T or p.T790M), and is metastatic, one recommended treatment would be Osimertinib. Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDA approved test, whose disease has progressed on or after EGFR TKI therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."
"If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.)."
"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.)."
"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.)."
"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Osimertinib. The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions, as detected by an FDA-approved test. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."
"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Osimertinib. The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 21 L858R mutations, as detected by an FDA-approved test. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."
"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 20 insertion), and is locally advanced or metastatic disease which has progressed on or after platinum-based chemotherapy., one recommended treatment would be Amivantamab-vmjw. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to amivantamab-vmjw for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. (Citation: Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf. Revised March 2024. Accessed March 4, 2024.)."
"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 20 insertion), and is locally advanced or metastatic disease which has progressed on or after platinum-based chemotherapy., one recommended treatment would be Mobocertinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. (Citation: Takeda Pharmaceuticals America, Inc. Exkivity (mobocertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf. Revised September 2021. Accessed September 16th, 2021.)."
"If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.)."
"If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.)."
"If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.)."
"If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2045C>G or p.A682G), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.)."
"If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.)."
"If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.)."
"If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.)."
"If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.)."
"If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH1, and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are greater than or equal to 75 years of age and who have comorbidities that preclude the use of intensive induction chemotherapy. relapsed or refractory aml., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are greater than or equal to 75 years of age and who have comorbidities that preclude the use of intensive induction chemotherapy. relapsed or refractory aml., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a cholangiocarcinoma patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a cholangiocarcinoma patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH1, and is newly diagnosed aml who are greater than or equal to 75 years of age and who have comorbidities that preclude the use of intensive induction chemotherapy. relapsed or refractory aml., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a cholangiocarcinoma patient has a somatic variant in gene IDH1, and is locally advanced or metastatic, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.419G>A or p.R140Q), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.516G>T or p.R172S), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH2 (c.515G>A or p.R172K), and is relapsed or refractory, one recommended treatment would be Enasidenib. The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Citation: Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.)."
"If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is unresectable and/or metastatic, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.)."
"If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, one recommended treatment would be Imatinib. FDA-approved for (1) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) and (2) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.)."
"If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.)."
"If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.)."
"If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.)."
"If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.)."
"If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, one recommended treatment would be Sunitinib. The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate. (Citation: Pfizer, Inc. Sutent (sunitinib malate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf. Revised August 2020. Accessed November 12, 2020.)."
"If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), one recommended treatment would be Sunitinib. The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate. (Citation: Pfizer, Inc. Sutent (sunitinib malate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf. Revised August 2020. Accessed November 12, 2020.)."
"If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), one recommended treatment would be Sunitinib. The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate. (Citation: Pfizer, Inc. Sutent (sunitinib malate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf. Revised August 2020. Accessed November 12, 2020.)."
"If a non-small cell lung cancer patient has a somatic variant in gene KRAS (c.34G>T or p.G12C), and is locally advanced or metastatic disease, one recommended treatment would be Sotorasib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sotorasib, a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy. (Citation: Amgen Inc. Lumakras (sotorasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.)."
"If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.)."
"If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.)."
"If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a gastrointestinal stromal tumor patient has a somatic variant in gene PDGFRA, and is unresectable or metastatic, one recommended treatment would be Avapritinib. The U.S. Food and Drug Administration (FDA) granted approval to avapritinib, a KIT inhibitor, for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor alpha (PDGFRA) exon 18 variant, including PDGFRA p.D842V. (Citation: Blueprint Medicines Corporation. Ayvakit (avapritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf. Revised June 2021. Accessed September 2nd, 2021.)."
"If a gastrointestinal stromal tumor patient has a somatic variant in gene PDGFRA (c.2525A>T or p.D842V), and is unresectable or metastatic, one recommended treatment would be Avapritinib. The U.S. Food and Drug Administration (FDA) granted approval to avapritinib, a KIT inhibitor, for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor alpha (PDGFRA) exon 18 variant, including PDGFRA p.D842V. (Citation: Blueprint Medicines Corporation. Ayvakit (avapritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf. Revised June 2021. Accessed September 2nd, 2021.)."
"If a breast cancer patient has a somatic variant in gene PIK3CA, and is advanced or metastatic, one recommended treatment would be Alpelisib. Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. (Citation: Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.)."
"If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.)."
"If a subependymal giant cell astrocytoma patient has a somatic variant in gene TSC1, one recommended treatment would be Everolimus. Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection (Citation: Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.)."
"If a subependymal giant cell astrocytoma patient has a somatic variant in gene TSC2, one recommended treatment would be Everolimus. Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection (Citation: Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.)."
"If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a fallopian tube cancer patient has a germline variant in gene BRCA1, and is treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a epithelial ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a fallopian tube cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a ovarian cancer patient has a germline variant in gene BRCA1, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a fallopian tube cancer patient has a germline variant in gene BRCA1, and is treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a ovarian cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a fallopian tube cancer patient has a germline variant in gene BRCA2, and is treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, treated with three or more prior lines of chemotherapy, one recommended treatment would be Niraparib. The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy. (Citation: GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.)."
"If a epithelial ovarian cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a fallopian tube cancer patient has a germline variant in gene BRCA2, and is advanced, treated with three or more prior lines of chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.)."
"If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.)."
"If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.)."
"If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Neratinib. The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.)."
"If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.)."
"If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.)."
"If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.)."
"If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.)."
"If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.)."
"If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.)."
"If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.)."
"If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.)."
"If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.)."
"If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.)."
"If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.)."
"If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.)."
"If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.)."
"If a any solid tumor patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is advanced or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.)."
"If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.)."
"If a myeloid/lymphoid neoplasms patient has a rearrangement in gene FGFR1, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.)."
"If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.)."
"If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>G or p.R132G), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>A or p.R132S), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.)."
"If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>T or p.R132L), one recommended treatment would be Olutasidenib. The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Citation: Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.)."
"If a non-small cell lung cancer patient has a somatic variant in gene KRAS (c.34G>T or p.G12C), and is locally advanced or metastatic disease, one recommended treatment would be Adagrasib. The U.S. Food and Drug Administration (FDA) has granted approval to adagrasib for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy. (Citation: Mirati Therapeutics, Inc. Krazati (adagrasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf. Revised Dec 2022. Accessed January 5th, 2023.)."
"If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.)."
"If a breast cancer patient has a somatic variant in gene ESR1, and is advanced or metastatic, one recommended treatment would be Elacestrant. The U.S. Food and Drug Administration (FDA) has granted approval to elacestrant for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. (Citation: Stemline Therapeutics, Inc. Orserdu (elacestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf. Revised January 2023. Accessed February 2, 2023.)."
"If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.)."
"If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.)."
"If a prostate cancer patient has a somatic variant in gene ATM, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a prostate cancer patient has a somatic variant in gene ATR, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a prostate cancer patient has a somatic variant in gene CDK12, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a prostate cancer patient has a somatic variant in gene CHEK2, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a prostate cancer patient has a somatic variant in gene FANCA, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a prostate cancer patient has a somatic variant in gene MLH1, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a prostate cancer patient has a somatic variant in gene NBN, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.)."
"If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.)."
"If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.)."
"If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.)."
"If a endometrial cancer patient is MSI-high, and is primary advanced or recurrent, one recommended treatment would be Dostarlimab-gxly. The U.S. Food and Drug Administration (FDA) granted approval to dostarlimab-gxly in combination with carboplatin and paclitaxel, followed by single agent dostarlimab-gxly, for the treatment of adult patients primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite-instability-high. (Citation: GlaxoSmithKline LLC. Jemperli (dostarlimab-gxly) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s006lbl.pdf. Revised July 2023. Accessed September 6, 2023.)."
"If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.)."
"If a myelodysplastic syndromes patient has a somatic variant in gene IDH1, and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a myelodysplastic syndromes patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a myelodysplastic syndromes patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is relapsed or refractory, one recommended treatment would be Ivosidenib. The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a non-small cell lung cancer patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is metastatic, one recommended treatment would be Binimetinib + Encorafenib. The U.S. Food and Drug Administration (FDA) approved encorafenib in combination with binimetinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test. (Citation: Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a breast cancer patient has a somatic variant in gene PIK3CA, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.)."
"If a breast cancer patient has a somatic variant in gene AKT1, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.)."
"If a breast cancer patient has a somatic variant in gene PTEN (nonsense), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.)."
"If a breast cancer patient has a somatic variant in gene PTEN (frameshift), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.)."
"If a breast cancer patient has a somatic variant in gene PTEN (splice site), and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.)."
"If a breast cancer patient has a copy number in gene PTEN, and is locally advanced or metastatic, one recommended treatment would be Capivasertib + Fulvestrant. The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations. (Citation: AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.)."
"If a breast cancer patient has a copy number in gene ERBB2, and is advanced or metastatic, one recommended treatment would be Neratinib + Capecitabine. The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. (Citation: Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.)."
"If a erdheim-chester disease patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), one recommended treatment would be Vemurafenib. The U.S. Food and Drug Administration (FDA) approved vemurafenib for the treatment of patients with Erdheim-Chester disease and whose tumors harbor a BRAF V600 mutation. (Citation: Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed November 12, 2020.)."
"If a erdheim-chester disease patient has a somatic variant in gene BRAF (c.1798_1799GT>AA or p.V600K), one recommended treatment would be Vemurafenib. The U.S. Food and Drug Administration (FDA) approved vemurafenib for the treatment of patients with Erdheim-Chester disease and whose tumors harbor a BRAF V600 mutation. (Citation: Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed November 12, 2020.)."
"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 20 insertion), and is locally advanced or metastatic disease which has progressed on or after platinum-based chemotherapy., one recommended treatment would be Amivantamab-vmjw + Carboplatin + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test. (Citation: Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf. Revised March 2024. Accessed March 4, 2024.)."
"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."
"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."
"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Osimertinib. The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or an exon 21 p.L858R variant, as detected by an FDA-approved test. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."
"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Osimertinib. The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or an exon 21 p.L858R variant, as detected by an FDA-approved test. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."
"If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."
"If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."
"If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.)."
"If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.)."
"If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is locally advanced or metastatic, one recommended treatment would be Repotrectinib. The U.S. Food and Drug Administration (FDA) granted approval to repotrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Citation: Bristol-Myers Squibb Company. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf. Revised November 2023. Accessed December 5, 2023.)."
"If a prostate cancer patient has a somatic variant in gene MRE11, and is metastatic castration-resistant, one recommended treatment would be Enzalutamide + Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.)."
"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.)."
"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib. The U.S. Food and Drug Administration (FDA) granted approval to ponatinib for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) for whom no other kinase inhibitors are indicated. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.)."
"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib. The U.S. Food and Drug Administration (FDA) granted approval to ponatinib for the treatment of adult patients with T315I-positive Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.)."
"If a acute lymphoblastic leukemia patient has a somatic variant in gene ABL1 (c.944C>T or p.T315I), one recommended treatment would be Ponatinib. The U.S. Food and Drug Administration (FDA) granted approval to ponatinib for the treatment of adult patients with T315I-positive Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.)."
"If a chronic myeloid leukemia patient has a somatic variant in gene ABL1 (c.944C>T or p.T315I), one recommended treatment would be Ponatinib. The U.S. Food and Drug Administration (FDA) granted approval to ponatinib for the treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) in the chronic phase, accelerated phase, or blast phase. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.)."
